Aetna Incorporation, the third-largest American Health Insurance Company, showed a significant 42% rise in the revenue of the 2010’s second-quarter, rubbing out the earlier medical losses.

Earnings soared to attain a value of $3.05 to $3.15 a share, although experts and economists never expected these earnings to exceed the $2.75 to $2.85. In comparison to the net income of $346.6 million in 2009, Aetna reported a net income of $491 million in 2010.

The rise was directly attributed to the unexpected drop in the flu patients, as well as, in the severity of the flu attacks, during that period. Aetna executives reported that, as a result of the unanticipated increase in profits and the consequential decrease in costs, the Company would allocate more funds in the annual drug spending. The potential drug budget would probably reach $9.5 billion.

The recently-announced cutbacks in the health care budgets all around the world led the experts to question the Company’s ability to sustain such profits for the next fiscal year.

In a statement, the Company confirmed a 12-year deal with CVS Caremark Corporation to handle the distribution of the former’s medicine production, managing pharmacy services and benefits. Although, Aetna refrained from giving any information regarding the value of the contract, the Company stressed that, as a result of this contract, CVS would be granted an access to more than 9.7 million customers.